A fatty acid oxidation-dependent metabolic shift regulates the adaptation of BRAF-mutated melanoma to MAPK inhibitors

PURPOSE: Treatment of BRAF(V600E)-mutant melanomas with mitogen-activated protein kinase inhibitors (MAPKi) results in significant tumor regression, but acquired resistance is pervasive. To understand non-mutational mechanisms underlying the adaptation to MAPKi and to identify novel vulnerabilities...

Full description

Saved in:
Bibliographic Details
Published in:Clin Cancer Res
Main Authors: Aloia, Andrea, Müllhaupt, Daniela, Chabbert, Christophe D., Eberhart, Tanja, Flückiger-Mangual, Stefanie, Vukolic, Ana, Eichhoff, Ossia, Irmisch, Anja, Alexander, Leila T., Scibona, Ernesto, Frederick, Dennie T., Miao, Benchun, Tian, Tian, Cheng, Chaoran, Kwong, Lawrence N., Wei, Zhi, Sullivan, Ryan J., Boland, Genevieve M., Herlyn, Meenhard, Flaherty, Keith T., Zamboni, Nicola, Dummer, Reinhard, Zhang, Gao, Levesque, Mitchell P., Krek, Wilhelm, Kovacs, Werner J.
Format: Artigo
Language:Inglês
Published: 2019
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6906212/
https://ncbi.nlm.nih.gov/pubmed/31375515
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-0253
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items